MediFind's AI 'Chloe' Enters Crowded Field to Guide Patient Care

WILMINGTON, Del. – July 21, 2026 – In an increasingly digital healthcare landscape, finding the right doctor remains a frustratingly analog ordeal for many. Patients often find themselves navigating a labyrinth of insurance directories, provider websites, and long hold times, a process that can lead to incorrect bookings or giving up on the search altogether. Addressing this critical pain point, MediFind, the data-science-driven provider directory acquired by patient activation leader Phreesia, today announced the launch of Chloe, an AI-powered chatbot designed to act as a personal guide for patients seeking care.

The new tool aims to transform the daunting task of finding a provider into a streamlined, conversational experience. By asking a series of targeted questions, Chloe gathers essential patient information upfront to deliver tailored provider matches from MediFind's extensive database of over two million clinicians. The launch represents a significant strategic move by Phreesia, leveraging its July 2023 acquisition of MediFind to deepen its capabilities in patient navigation and solidify its market position.

The AI Navigator: A Guided Journey to the Right Doctor

Unlike traditional search directories that rely on basic filters like specialty and location, Chloe is engineered to provide a more nuanced and guided journey. When a patient initiates a chat on MediFind.com, they are led through a short, conversational intake about the type of care they need, their location, insurance plan, and any personal preferences. The goal is to move beyond simple keyword matching and understand the patient's specific context.

“We built Chloe because we know that finding the right provider is about more than search results, it’s about guidance,” said David Linetsky, President of Phreesia Network Solutions, in the announcement. “By asking the right questions up front, we make it easier for patients to find a provider who actually fits their care needs.”

The real power behind Chloe lies in MediFind’s sophisticated data analytics engine, which was built to identify true medical expertise. The platform’s algorithms continuously analyze vast datasets—including over a million research reports, clinical trials, and professional presentations annually—to assess a physician's focus and experience with specific conditions. This data-driven approach is particularly crucial for patients managing complex, chronic, or rare diseases, where connecting with a leading expert can directly impact treatment outcomes. Instead of just showing a list of cardiologists, MediFind's technology aims to identify the cardiologist with deep, demonstrable expertise in a patient's specific rare heart condition.

Once the intake is complete, Chloe presents a curated list of provider matches. Patients can then review detailed profiles, compare their options, and, when ready, request an appointment directly through the platform. By capturing the necessary details at the beginning of the process, the system is designed to reduce the friction that often leads to scheduling setbacks and administrative errors for both patients and provider offices.

A Strategic Play in Patient Activation

The launch of Chloe is more than just a new product feature; it is a calculated strategic expansion for its parent company, Phreesia. A dominant force in patient activation, Phreesia's platform facilitated over 180 million patient visits in 2025, touching roughly one in every six appointments in the United States. Its core business has long focused on streamlining the patient experience at the point of care through digital solutions for intake, scheduling, and payments. The acquisition of MediFind, and now the deployment of Chloe, extends Phreesia’s reach to the very beginning of the patient journey: the search for care.

By integrating MediFind’s advanced patient-provider matching capabilities, Phreesia creates a more comprehensive, end-to-end ecosystem. The company can now engage patients before they have even chosen a provider, guide them to a physician within its network, and then seamlessly manage their intake, scheduling, and follow-up. This strategy not only enhances the patient experience but also provides immense value to the healthcare organizations that use Phreesia's services by delivering well-matched, pre-qualified patients to their digital front door.

This move aligns with Phreesia's broader investment in artificial intelligence across its product suite, which already includes AI-powered self-scheduling and voice automation tools. By adding an intelligent provider search function, the company reinforces its position as a technology leader aiming to solve systemic inefficiencies in healthcare. For a health system, the integration promises a powerful tool for patient acquisition, administrative efficiency, and potentially, improved patient retention by ensuring a better initial match.

Beyond the Algorithm: Promise and Pitfalls of AI Matching

While the promise of an AI-powered care navigator is compelling, MediFind's Chloe enters a competitive and complex arena. Established players like Zocdoc have already conditioned millions of users to book appointments online, and many large health systems have invested heavily in their own provider directories. Chloe’s differentiation hinges on the superior quality of its AI-driven matching, particularly for the complex cases that are MediFind's specialty.

However, the reliance on AI also raises critical questions. Chief among them are data privacy and security. As a HIPAA business associate, Phreesia is bound by strict regulations, but the conversational collection of sensitive health information requires unwavering vigilance to maintain patient trust. Transparency is another hurdle. Patients and providers alike will want to understand the criteria behind Chloe’s recommendations to ensure they are fair and unbiased. The risk of algorithmic bias, which can perpetuate existing health disparities if not carefully monitored and mitigated, remains a significant concern for any AI application in healthcare.

Furthermore, the definition of the 'right' provider is deeply personal and often transcends quantifiable data. Factors like bedside manner, communication style, and cultural competency are difficult for an algorithm to assess. While AI can dramatically narrow the field, the human element of choice remains paramount. The success of tools like Chloe will depend on their ability to empower patients with better information, not replace their judgment.

For providers, the challenge will be ensuring the data fueling the algorithm—from insurance accepted to real-time availability—is impeccably accurate. As Chloe begins its work guiding patients through the intricate healthcare system, its ultimate success will be measured not just by the sophistication of its code, but by its ability to foster trust and genuinely improve access to the right care at the right time.